12:00 AM
 | 
Sep 25, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 9/22 cls
Alnylam (ALNY) ThinkEquity Andrew McDonald Discontinued NA -9% $13.18
The firm dropped coverage of the infectious disease and neurology company after McDonald's departure.
Arena (ARNA) AG Edwards Aaron Reames New Buy 2% $12.22
Natexis Bleichroeder John LeCroy New NA
Reames set an $18 target. He expects six-month echocardiogram safety data in mid-2007 from a Phase III trial of lorcaserin (APD356) to treat obesity. He believes...

Read the full 556 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >